Peter Doyle - Revision history

Claire Robinson at 23:14, 4 April 2009

2009-04-04T23:14:31Z

Claire Robinson at 23:14, 4 April 2009

2009-04-04T23:14:02Z

Claire Robinson at 23:12, 4 April 2009

2009-04-04T23:12:18Z

Claire Robinson at 23:10, 4 April 2009

2009-04-04T23:10:48Z

Claire Robinson at 19:34, 19 February 2009

2009-02-19T19:34:57Z

David at 21:55, 12 October 2007

2007-10-12T21:55:34Z

David at 21:54, 12 October 2007

2007-10-12T21:54:51Z

Michael at 11:02, 29 November 2005

2005-11-29T11:02:22Z

Michael at 13:14, 25 November 2005

2005-11-25T13:14:24Z

Michael at 13:12, 25 November 2005

2005-11-25T13:12:28Z

New page

Until summer 2003 Dr Peter Doyle was Chairman of the UKâ€™s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department

Director of [[Sourcewatch:Syngenta|Syngenta]]. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University. Director of Syngenta. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the Biotechnology andBiological Sciences Research Council. He served as directorof ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.Director of Syngenta. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the Biotechnology andBiological Sciences Research Council. He served as directorof ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.Doyle is also a director of Syngenta and when he first took up his BBSRC post in 1998 he was still the executive director of the Zeneca Group plc (1993-1999). In 1996 Zeneca introduced the first GM food into UK supermarkets, a tomato paste made from GM tomatoes. Zeneca's R&D director, Ed Dart, who oversaw that project served on the Council of the BBSRC.

Zeneca featured twice on Friends of the Earth's '50 Filthiest Factories' list for 1996. Doyle has been a member of the Royal Commission on Environmental Protection. Prior to Zeneca Doyle was a Director of ICI (1989-1993)

Peter Doyle left Zeneca at the time of its 1999 merger with Swedish pharmaceutical company Astra, to form AstraZeneca. The 'crop science' part of the company subsequently became part of GM giant Syngenta via a merger with Novartis.

Zeneca under Doyle committed itself to investing Â£50 million in the John Innes Centre in Norwich, which is funded by the BBSRC and Lord Sainsbury through his Gatsby Charitable Foundation.

On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame Bridget Ogilvie, and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.

@@ Line 9: / Line 9: @@
 Zeneca under Doyle committed itself to investing £50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his [[Gatsby Charitable Foundation]].
-On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the [[Nuffield Foundation]] and the [[AstraZeneca]] Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the [[Medical Research Council]], and the Prime Minster's Advisory Committee on Science and Technology.
+On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the [[Nuffield Foundation]] and the [[AstraZeneca]] Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the [[Medical Research Council]] and the Prime Minister's Advisory Committee on Science and Technology.
 ==Notes==
 <references/>
 [[Category:GM|Doyle, Peter]]

← Older revision		Revision as of 23:14, 4 April 2009
Line 1:		Line 1:
−	Until summer 2003 Dr '''Peter Doyle''' was Chairman of the UK's main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]~~'s Government department, the ministry of~~ science.	+	Until summer 2003 Dr '''Peter Doyle''' was Chairman of the UK's main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by the ministry of science. Until 2006 [[Lord David Sainsbury]] was science minister.

	He is also a director of [[Syngenta]]. Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of [[ICI]] from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in pure science and a PhD in chemistry from Glasgow University.		He is also a director of [[Syngenta]]. Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of [[ICI]] from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in pure science and a PhD in chemistry from Glasgow University.

@@ Line 3: / Line 3: @@
 He is also a director of [[Syngenta]]. Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of [[ICI]] from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in pure science and a PhD in chemistry from Glasgow University.
-Zeneca featured twice on Friends of the Earth's '50 Filthiest Factories' list for 1996. Doyle has been a member of the Royal Commission on Environmental  Protection. Prior to Zeneca Doyle was a Director of ICI (1989-1993)
+Zeneca featured twice on Friends of the Earth's '50 Filthiest Factories' list for 1996. Doyle has been a member of the Royal Commission on Environmental  Protection. Prior to working for Zeneca, Doyle was a Director of [[ICI]] (1989-1993).
 Doyle left Zeneca at the time of its 1999 merger with Swedish pharmaceutical company Astra, to form AstraZeneca. The 'crop science' part of the company subsequently became part of GM giant Syngenta via a merger with Novartis.
@@ Line 9: / Line 9: @@
 Zeneca under Doyle committed itself to investing £50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his [[Gatsby Charitable Foundation]].
-On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.
+On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the [[Nuffield Foundation]] and the [[AstraZeneca]] Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the [[Medical Research Council]], and the Prime Minster's Advisory Committee on Science and Technology.
 ==Notes==
 <references/>
 [[Category:GM|Doyle, Peter]]

@@ Line 1: / Line 1: @@
-Until summer 2003 Dr '''Peter Doyle''' was Chairman of the UK&#39;s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department, the ministry of science.
+Until summer 2003 Dr '''Peter Doyle''' was Chairman of the UK's main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department, the ministry of science.
 He is also a director of [[Syngenta]]. Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of [[ICI]] from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in pure science and a PhD in chemistry from Glasgow University.
@@ Line 13: / Line 13: @@
 ==Notes==
 <references/>
-[[Category:GM]]
+[[Category:GM|Doyle, Peter]]

@@ Line 1: / Line 1: @@
-Until summer 2003 Dr Peter Doyle was Chairman of the UK&#39;s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department
+Until summer 2003 Dr '''Peter Doyle''' was Chairman of the UK&#39;s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department, the ministry of science.
-Director of [[Syngenta]]. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of ICI from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.
+He is also a director of [[Syngenta]]. Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of [[ICI]] from 1989 until 1993 and of [[Zeneca]] Group PLC from1993 until April 1999. He holds a BS (Hons) degree in pure science and a PhD in chemistry from Glasgow University.
 Zeneca featured twice on Friends of the Earth's '50 Filthiest Factories' list for 1996. Doyle has been a member of the Royal Commission on Environmental  Protection. Prior to Zeneca Doyle was a Director of ICI (1989-1993)
-Peter Doyle left Zeneca at the time of its 1999 merger with Swedish pharmaceutical company Astra, to form AstraZeneca. The 'crop science' part of the company subsequently became part of GM giant Syngenta via a merger with Novartis.
+Doyle left Zeneca at the time of its 1999 merger with Swedish pharmaceutical company Astra, to form AstraZeneca. The 'crop science' part of the company subsequently became part of GM giant Syngenta via a merger with Novartis.
-Zeneca under Doyle committed itself to investing �50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his [[Gatsby Charitable Foundation]].
+Zeneca under Doyle committed itself to investing £50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his [[Gatsby Charitable Foundation]].
 On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.
@@ Line 13: / Line 13: @@
 ==Notes==
 <references/>

← Older revision		Revision as of 21:55, 12 October 2007
Line 10:		Line 10:

	On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.		On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.
		+
		+	==Notes==
		+	<references/>

@@ Line 1: / Line 1: @@
-Until summer 2003 Dr Peter Doyle was Chairman of the UKâ€™s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department
+Until summer 2003 Dr Peter Doyle was Chairman of the UK&#39;s main public funding body, the [[Biotechnology and Biological Sciences Research Council]] (BBSRC), which is overseen by [[Lord David Sainsbury]]'s Government department
@@ Line 11: / Line 11: @@
-Zeneca under Doyle committed itself to investing Â£50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his Gatsby Charitable Foundation.
+Zeneca under Doyle committed itself to investing million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his [[Gatsby Charitable Foundation]].
 On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.

@@ Line 2: / Line 2: @@
-Director of [[Sourcewatch:Syngenta|Syngenta]]. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University. Director of Syngenta. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the Biotechnology andBiological Sciences Research Council. He served as directorof ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.Director of Syngenta. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the Biotechnology andBiological Sciences Research Council. He served as directorof ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.Doyle is also a director of Syngenta and when he first took up his BBSRC post in 1998 he was still the executive director of the Zeneca Group plc (1993-1999). In 1996 Zeneca introduced the first GM food into UK supermarkets, a tomato paste made from GM tomatoes. Zeneca's R&D director, Ed Dart, who oversaw that project served on the Council of the BBSRC.
+Director of [[Sourcewatch:Syngenta|Syngenta]]. Peter Doyle served as Director of Oxagen, Avidex and Chairman of the [[Biotechnology and Biological Sciences Research Council]]. He served as director of ICI from 1989 until 1993 and of Zeneca Group PLC from1993 until April 1999. He holds a BS (Hons) degree in purescience and a PhD in chemistry from Glasgow University.
@@ Line 11: / Line 11: @@
-Zeneca under Doyle committed itself to investing Â£50 million in the John Innes Centre in Norwich, which is funded by the BBSRC and Lord Sainsbury through his Gatsby Charitable Foundation.
+Zeneca under Doyle committed itself to investing Â£50 million in the [[John Innes Centre]] in Norwich, which is funded by the BBSRC and [[Lord David Sainsbury]] through his Gatsby Charitable Foundation.
-On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame Bridget Ogilvie, and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.
+On leaving Zeneca, Peter Doyle joined the board of genomics company Oxagen Ltd (1999-2002). Doyle was also a non-executive director of Oxford Molecular PLC (1997-2000). He is a non-executive director of Avidex. He is also a trustee of the Nuffield Foundation and the AstraZeneca Science Teaching Trust, which is chaired by Dame [[Bridget Ogilvie]], and previously was a member of the Medical Research Council, and the Prime Minster's Advisory Committee on Science and Technology.